Hester BiosQ1 FY24

Hester Bios Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,324.6P/E: 33.7Market Cap: ₹2.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

No

0 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Animal Healthcare division is growing rapidly, now contributing 42% to the top line, up from 30% last year, driven by increased vaccine sales (e.g., PPR and LSD vaccines).
  • Vaccine business expected to increase as a percentage, though larger health products market will require more focus on health products for scale-up.
  • LSD immunization in India seen as repeatable business with annual vaccination; potential market linked to 9 crore cattle vaccinated recently.
  • African market growth is delayed due to economic and regulatory challenges but expected to pick up in 6-8 months; presence there positions Hester advantageously for future demand.
  • New generation vaccines (e.g., next-gen Brucella, Classical Swine Fever, Lumpy Skin Disease) under development to drive future growth.
  • Sales in pharma/trading products are currently one-time but could recur.
  • Overall revenue growth supported by expanded sales force and wider product reach.

See what Hester Bios management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No significant new capital expenditure (capex) is expected on existing projects; majority of expenditure is already done, currently in regulatory approval stage.
  • No mention of new fundraising through debt or equity for ongoing projects; the company feels well-covered financially for current projects.
  • Any new projects requiring finances would be separately addressed; currently, no such announcements.
  • Repurposing existing BSL-3 facility for vaccines will require nominal spend (estimated up to a couple of crores INR, possibly less than 50 lakhs INR), implying limited need for fresh funds.
  • Overall, no indication of immediate or planned fundraising through debt or equity as per the current transcript.

See what Hester Bios management said on order book — free account, 30 seconds.

Capex plans

No
  • Majority of the existing capex for ongoing projects has been completed; remaining expenditure is not expected to be significant as per CFO Nikhil Jhanwar.
  • Current focus is on regulatory approvals for completed capacity expansion, which will double overall vaccine manufacturing capacity.
  • The BSL-3 laboratory, initially for COVID vaccine production, is being repurposed for other vaccines (human/animal) with nominal additional spend estimated to be around INR 0.5 to 2 crores.
  • No significant new capital investment planned unless new projects arise.
  • Company is working on four new vaccine developments, leveraging existing infrastructure.
  • Strategic investment includes expanding into African markets despite short-term challenges, with backing from the Bill & Melinda Gates Foundation.

Track Hester Bios — get its next earnings analysis in your feed

How does Hester Bios rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisHester Bios
Rev 3Mar 3

How does Hester Bios rank in Pharmaceuticals & Biotechnology?

Compare Hester Bios against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →